Core Viewpoint - Shanghai Haixin Group's subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., has received approval for its Vitamin B6 injection to pass the consistency evaluation of quality and efficacy for generic drugs, enhancing its market competitiveness and experience for future drug development [1][6]. Group 1: Drug Information - The drug is named Vitamin B6 Injection, in the form of an injection with a specification of 1ml:0.1g, classified as a chemical drug [1]. - The approval number for the drug is H20258295, and it has been granted a 12-month validity period [1]. - The drug is indicated for the prevention and treatment of Vitamin B6 deficiency, as well as for various conditions such as pregnancy-related issues and certain metabolic disorders [2][3][4]. Group 2: Market Situation - Vitamin B6 is a water-soluble vitamin that cannot be synthesized by the human body and must be obtained through diet or intravenous injection [7]. - The injection is classified as a Category A drug under national medical insurance and is included in the national essential drug list, indicating its widespread application in disease prevention and treatment [7]. - According to the Minet database, the sales revenue of Vitamin B6 injection in public medical institutions in China is projected to be approximately RMB 304 million in 2024 [7]. Group 3: Impact on the Company - The approval of Vitamin B6 injection enhances the market competitiveness of Jiangxi Gannan Haixin and contributes to the accumulation of experience for future drug development [6]. - The current operational performance of the company is not expected to be significantly impacted by this approval [6].

Group 1 - The company Shanghai Haixin Group Co., Ltd. has provided a guarantee for its wholly-owned subsidiary, Shanghai Haixin Logistics Co., Ltd., for a fixed asset loan of RMB 20 million from Shanghai Rural Commercial Bank, which will be used for the renovation of its factory [2][4] - The guarantee was approved by the company's board of directors during the eighth meeting of the eleventh session, with a maximum guarantee amount set at RMB 30 million [3][6] - The collateral for the loan is a property located at No. 121, Zhenye Road, Dongjing Town, Songjiang District, Shanghai [5][6] Group 2 - The loan is scheduled for a term from January 12, 2026, to January 11, 2031, and is aimed at meeting the financing needs for the factory renovation, aligning with national policies on urban renewal and industrial upgrading [4][6] - As of the announcement date, the total amount of guarantees provided by the company to its subsidiaries is RMB 143.75 million, which accounts for 3.32% of the company's audited net assets of RMB 4.334 billion for the year 2024, with no overdue guarantees or guarantees involved in litigation [6]

Core Viewpoint - The company, Shanghai Haixin Group Co., Ltd., will participate in the 2025 Shanghai-listed companies' collective performance briefing for the third quarter, aiming to enhance investor understanding of its operational results and financial status [2][8]. Group 1: Meeting Details - The investor briefing will be held online on November 13, 2025, from 15:00 to 16:30 [6][7]. - The meeting will feature key company executives, including Chairman Deng Haibin, Independent Director Li Zhijun, President Ren Xiaowei, CFO Zhu Xifeng, and Secretary of the Board Zhang Gao [4]. - Investors can participate via the Shanghai Stock Exchange Roadshow Center website [5][6]. Group 2: Participation and Interaction - Investors can submit questions from November 6 to November 12, 2025, through the Roadshow Center or via the company's email [5][6]. - The company will address commonly asked questions during the briefing, ensuring a comprehensive interaction with investors [3][5]. Group 3: Contact Information - For inquiries, investors can contact the company's secretariat office at 021-57698031 or via email at 600851@haixin.com [6].

Core Points - The company ensures the authenticity, accuracy, and completeness of the quarterly report, with all board members and senior management bearing legal responsibility for any false statements or omissions [2][3]. Financial Data - The financial statements for the third quarter are not audited, indicating that the figures presented are preliminary and subject to change [3][7]. - The report includes major accounting data and financial indicators, although specific figures are not provided in the text [3]. Non-Recurring Gains and Losses - The company has the option to classify certain items as non-recurring gains and losses, but it is noted that this section is applicable [4]. Shareholder Information - Information regarding the total number of common shareholders and the top ten shareholders is included, although specific details are not provided in the text [5]. Other Reminders - There are no additional important reminders regarding the company's operational status during the reporting period [6].

Group 1 - The board of directors of Shanghai Haixin Group Co., Ltd. held its 13th meeting of the 11th session on October 15, 2025, in accordance with relevant laws and regulations [2][3] - The meeting was attended by all 9 directors, with some participating via communication methods [2] - The board unanimously approved the strategic plan for 2026-2030, focusing on strengthening the company's core business and exploring new growth opportunities through mergers and acquisitions [3] Group 2 - The strategic plan aims to adapt to macroeconomic changes and industry transformations while enhancing the company's operational capabilities [3] - The company will pursue a dual strategy of "industrial operation + investment and mergers" to drive innovation and high-quality development [3] - The property management sector is expected to continue providing stable cash flow to support the company's growth initiatives [3]

Group 1 - The company has approved an investment of up to 30 million RMB in the Yuanhe Puhua Industrial M&A Fund, considering the fund's risk diversification and past investment returns [2] - As of June 20, 2025, the company and its wholly-owned subsidiary have committed 30 million RMB to the fund and are acting as limited partners [3] - The fund has successfully raised a total of 2.473 billion RMB, with the partnership term extended from eight to ten years [4] Group 2 - The fund is registered with the China Securities Investment Fund Industry Association, with a registration date of September 27, 2024, and a change date of October 9, 2025 [4][5] - The management of the fund is handled by Yuanhe Puhua Tongxin (Suzhou) Investment Management Co., Ltd., and the custodian is Industrial and Commercial Bank of China [4]

Core Points - The company has released its 2025 semi-annual report, which includes financial results and future development plans [1][2] - The board of directors confirmed the authenticity, accuracy, and completeness of the report, taking legal responsibility for its content [2] - The board meeting was held on August 25, 2025, with all nine directors participating and unanimously approving the semi-annual report [2] Financial Data - The semi-annual report contains key financial data, although specific figures are not detailed in the provided text [1] - The report has been reviewed by the company's audit committee before being submitted to the board for approval [2] Important Matters - The company has not reported any significant changes in its operating conditions during the reporting period [1] - A resolution was passed to approve a donation of 390,000 RMB by its subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., to the Jiangxi Red Cross Foundation, which is not expected to significantly impact the company's financial performance [3]

Meeting Overview - The shareholders' meeting was held on August 12, 2025, at the company's conference room in Shanghai [1] - The meeting was presided over by the chairman, Mr. Deng Haibin, and complied with the Company Law and Articles of Association [1] Attendance - All 9 current directors attended the meeting, with some participating via communication due to work commitments [2] - All 4 current supervisors attended, with some also participating via communication [2] - The board secretary and other senior executives were present at the meeting [2] Resolutions Passed - The proposal to cancel the supervisory board and amend the Articles of Association was approved [2] - The proposal to revise certain governance systems of the company was also approved [2] - All proposals received approval from the shareholders' meeting [2] Legal Verification - The meeting was witnessed by Guohao Law Firm, with lawyers Wang Bo and Su Chengzi present [3] - The legal opinion confirmed that the meeting's procedures and voting methods complied with relevant laws and regulations, and the resolutions made were valid [3] Announcement - The announcement was issued by Shanghai Haixin Group Co., Ltd. on August 13, 2025, under the securities code 600851 [5]

Core Viewpoint - Shanghai Haixin Group Co., Ltd. has successfully completed the transfer of 51.3249% equity in Shanghai Haixin Pharmaceutical Co., Ltd. to Chongqing Huisheng Yunjian Business Information Consulting Center for a total consideration of 23.0494 million yuan [2][3]. Group 1: Transaction Overview - The board of directors approved the equity transfer on September 25, 2023, and authorized the management to handle the transaction [3]. - The total transaction price for the equity transfer was set at 23.0494 million yuan [3]. - As of the announcement date, Haixin Asset has received a total of 21.8969 million yuan from Huisheng Yunjian, which accounts for 95% of the agreed transfer price [3]. Group 2: Payment Progress - The third payment of 1.1525 million yuan was recently received, completing the total payment for the equity transfer [4]. - The total amount received from Huisheng Yunjian for the equity transfer is now 23.0494 million yuan, marking the full recovery of the transfer price [4].

Group 1 - The company will hold its 2024 Annual General Meeting on June 18, 2025, at 14:00 in Shanghai [1][4] - The voting method for the meeting will combine on-site and online voting [1] - The online voting system will be provided by the Shanghai Stock Exchange, with voting available from 9:15 to 15:00 on the day of the meeting [2][7] Group 2 - The meeting will include a report from the independent directors for the 2024 fiscal year [5] - All proposals for the meeting were approved during the board and supervisory meetings held on April 17, 2025 [6] - There are no special resolutions or related party voting issues for this meeting [7] Group 3 - Shareholders must register to attend the meeting, with registration available on June 16, 2025 [16] - The company provides a reminder service for small and medium investors to ensure participation [8] - Shareholders holding multiple accounts can vote through any of their accounts, but repeated votes will be counted only once [9][10]